Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Novo Nordisk

Tracked across 84 events · 1141 articles · First seen Feb 02, 2025 · Last active Sep 24, 2026

Sentiment
16
Attention
8
Events
84
Relationships
26
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
8 85
Regulatory
Impact: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
6 75
Business
Impact: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
6 80
Tech
Impact: Novo Nordisk announced positive topline results from its HIBISCUS phase 3 trial for etavopivat, a drug for sickle cell disease, which is expected to lead to regulatory submission and potential market approval, significantly boosting the company's pipeline and market position.
Apr 20, 2026 · 7 articles
4 -70
Regulatory
Impact: Novo Nordisk is a pharmaceutical company facing multiple lawsuits alleging that its GLP-1 medications, Semaglutide and Semaglutide, caused NAION and that the company failed to adequately warn consumers about these risks. This could lead to significant financial and reputational damage.
May 22, 2026 · 7 articles
6 -75
Accidents
Impact: Novo Nordisk, a pharmaceutical giant, was the target of a major cyberattack by Fulcrum Securities, resulting in the theft of over a terabyte of sensitive data. The company refused to pay a $25 million ransom, leading to potential private sales of the stolen data, which could damage its reputation, intellectual property, and patient trust.
Jun 16, 2026 · 11 articles
4 40
Business
Impact: Novo Nordisk launched Awiqli, its once-weekly insulin, in India, enhancing its product portfolio and competitive edge in the diabetes market.
Jul 09, 2026 · 21 articles
1 10
Business
Impact: Novo Nordisk is executing the share repurchase programme, repurchasing its own B shares as part of a DKK 15 billion buyback plan.
May 26, 2026 · 22 articles
4 80
Regulatory
Impact: Novo Nordisk is the drug manufacturer; the approval expands Wegovy's indication in India, potentially increasing sales and market share in the obesity and metabolic disease market.
Jul 17, 2026 · 13 articles
4 -30
Business
Impact: Novo Nordisk is the sponsor and developer of ziltivekimab; the trial failure will result in an impairment charge and may negatively impact investor sentiment, though the company maintains its 2026 outlook.
Jul 31, 2026 · 6 articles
6 60
Business
Impact: Central player; shares up 35% from March low, launching oral Semaglutide and suing Lilly, but faces competition and past profit warnings.
Aug 03, 2026 · 6 articles
4 70
Business
Impact: Novo Nordisk is the primary beneficiary, gaining access to AWS's AI and cloud capabilities to accelerate drug discovery and modernize operations, potentially improving its pipeline and efficiency.
Aug 10, 2026 · 7 articles
4 80
Business
Novo Nordisk announced positive results from the STEP Young phase 3 trial evaluating once-weekly semaglutide in children aged 6 to under 12 with obesity. The trial met its primary endpoint, showing superior BMI reduction at…
Impact: As the developer of semaglutide, Novo Nordisk stands to benefit from expanded indications and potential revenue growth.
Sep 07, 2026 · 7 articles
4 20
Business
Novo Nordisk and Anthropic announced a collaboration on September 16, 2026, aimed at accelerating the development of new medicines using Anthropic's Claude AI models and the Claude Science research workbench. The Danish drugmaker will initially…
Impact: Novo Nordisk is the central party, gaining access to Anthropic's Claude models and Claude Science to accelerate drug discovery and AI-driven software development. The deal supports its ambition to become the world's most AI-driven healthcare company and could improve R&D efficiency.
Sep 16, 2026 · 20 articles
6 70
Domestic
Impact: Novo Nordisk's drugs, Semaglutide and Tirzepatide, are among those that will be reimbursed in France, leading to increased market access and sales for the company in Europe. The company's General Manager and CEO welcomed the decision.
May 28, 2026 · 6 articles
4 -35
Regulatory
Hundreds of patients in the United States have filed personal injury lawsuits against Novo Nordisk and Eli Lilly and Company, alleging that widely used GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity caused a…
Impact: Primary defendant facing more than 90 lawsuits in New Jersey state court and separate federal cases over NAION claims tied to Ozempic and Wegovy. The litigation and potential label changes pose a material liability and reputational risk to its GLP-1 franchise.
Sep 21, 2026 · 20 articles
4 80
Regulatory
Impact: Novo Nordisk developed Semaglutide (semaglutide), and its collaboration with the United Arab Emirates — Emirates Drug Establishment led to the approval of the oral formulation in the United Arab Emirates, expanding its market reach for this significant treatment.
Jun 01, 2026 · 6 articles
4 60
Domestic
Impact: Novo Nordisk's semaglutide is the drug being tested; positive results could expand its approved uses and market, though the trial is early-stage.
Jul 30, 2026 · 6 articles
4 60
Business
Impact: Novo launched the first once-weekly GLP-1 in China and is revamping its marketing under new president Cai Yan to better compete. Its market position is strong but faces increasing competition.
Aug 24, 2026 · 6 articles
8 70
Tech
Impact: Novo Nordisk>>> produces GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
4 75
Tech
Impact: Manufacturer of semaglutide, the GLP-1 drug tested in the PMOS trials; positive results could expand its approved indications and market.
Aug 15, 2026 · 12 articles
4 70
Tech
A study led by NYU Langone Health, published in the journal Pediatrics on September 4, 2026, found that prescriptions for GLP-1 weight-loss drugs (Saxenda, Wegovy, Zepbound) among US children aged 8-11 with obesity increased 310-fold…
Impact: Manufacturer of Saxenda and Wegovy; rising pediatric prescriptions could expand market.
Sep 04, 2026 · 7 articles
4 -25
Tech
A study published in Clinical Nutrition identified 15 reported cases of Wernicke encephalopathy, a rare and potentially life-threatening neurological disorder caused by severe vitamin B1 (thiamine) deficiency, in patients taking GLP-1 receptor agonists. Most cases…
Impact: Maker of semaglutide-based Ozempic, Wegovy and Rybelsus, the drugs most frequently linked to the reported Wernicke encephalopathy cases. The negative safety headline could pressure its shares and invite regulatory scrutiny, though causation is unproven.
Sep 11, 2026 · 6 articles
3 30
Business
Impact: Novo Nordisk is outsourcing cartridge fill-finish manufacturing services to Biopharmaceutical, which could streamline its production and supply chain.
Jun 30, 2026 · 6 articles
6 -30
Tech
Impact: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Jan 08, 2026 · 6 articles
4 -30
Tech
Impact: Novo Nordisk, the manufacturer of Semaglutide, is facing scrutiny due to reports of severe adverse reactions experienced by Sarah-Jayne Crawford. They have issued a statement acknowledging gallstones as a common potential adverse reaction.
Apr 13, 2026 · 6 articles
6 70
Tech
Impact: Novo Nordisk is the manufacturer of Semaglutide, and the positive research findings could lead to expanded market opportunities and increased demand for their GLP-1 drugs.
Jun 02, 2026 · 6 articles
2 10
Business
Impact: Novo Nordisk gains access to evaluate a novel delivery method for semaglutide, potentially expanding its weight management portfolio.
Jul 07, 2026 · 6 articles
3 50
Business
Impact: Novo Nordisk developed Kyinsu and sees its first global commercialization in China, expanding its diabetes treatment portfolio and market reach.
Jul 20, 2026 · 6 articles
4 20
Tech
Impact: As the manufacturer of Ozempic, Novo Nordisk is central to the debate. Positive observational studies could support sales, but expert caution and lack of randomized trial confirmation may limit upside. The company's stock may see volatility based on headlines.
Jul 13, 2026 · 6 articles
3 -20
Regulatory
Impact: Novo Nordisk's Wegovy is one of the GLP-1 drugs being prescribed via telehealth; the study may lead to stricter oversight that could affect sales.
Jul 07, 2026 · 6 articles
+ 54 more events View on Dashboard
45 Novo Nordisk discontinued patent litigation Hims & Hers HealthHims & Hers Securities...
45 Novo Nordisk disappointed with strategy updateEli Lilly GLP-1 Selloff...
Hims & Hers Health competitor ↔ Novo Nordisk Novo Nordisk terminated its distribution partnership with Hims & Hers Health and
Hims & Hers Health competitor ↔ Novo Nordisk Hims & Hers Health is facing legal threats from Novo Nordisk after their brief d
Eli Lilly and Company ↔ Novo Nordisk
Eli Lilly and Company ↔ Novo Nordisk
Pfizer ↔ Novo Nordisk
Pfizer ↔ Novo Nordisk
Sanofi ↔ Novo Nordisk
Sanofi ↔ Novo Nordisk
Roche ↔ Novo Nordisk
Roche ↔ Novo Nordisk
IBM ↔ Novo Nordisk
IBM ↔ Novo Nordisk
Denmark ↔ Novo Nordisk
Denmark ↔ Novo Nordisk
European Union ↔ Novo Nordisk
European Union ↔ Novo Nordisk
China ↔ Novo Nordisk
China ↔ Novo Nordisk
United States ↔ Novo Nordisk
United States ↔ Novo Nordisk
Donald Trump ↔ Novo Nordisk
Donald Trump ↔ Novo Nordisk
India ↔ Novo Nordisk
India ↔ Novo Nordisk
ERGEN INTELLIGENCE
Track Novo Nordisk live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.